Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
Overall, the findings from these two recently completed cardiovascular outcomes trials suggest that the increases in HR associated with the short-acting GLP-1 RA, lixisenatide, or the long-acting GLP-1 RA, liraglutide, do not lead to an increased risk of major adverse cardiac events in patients with T2DM and high cardiovascular risk
M.GearyN.BartnessT
Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance
The final word (no fluff): If youre in the clinic with a patient who meets criteria for bariatric surgery, and youre already talking about GLP-1s or theyve tried one dont wait to stitch the pathways together
US$ 27.87
US$ 22.28
US$ 27.23
US$ 20.09
